Skip to main content
. Author manuscript; available in PMC: 2013 Nov 9.
Published in final edited form as: Clin Cancer Res. 2012 Feb 28;18(8):10.1158/1078-0432.CCR-11-2830. doi: 10.1158/1078-0432.CCR-11-2830

Figure 2.

Figure 2

Kaplan-Meier estimates illustrating (A) Overall survival (OS) and (B) Relapse free survival (RFS) of patients by total cMET in Hormone receptor positive breast cancer. Kaplan-Meier estimates illustrating (C) Overall survival (OS) and (D) Relapse free survival (RFS) of patients by p-cMET in HER2 positive breast cancer. High: total cMET > 0, Low: total cMET ≤ 0. High: p-cMET > 0.35, Low: p-cMET ≤ 0.35.